( MENAFN - GlobeNewsWire - Nasdaq) Outset Medical features patient experience poster presentations at Kidney Week 2024 Consensus recommendations for use of catheters in home hemodialysis patients published in Kidney medicine SAN JOSE, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Outset Medical, Inc.
(Nasdaq: OM) (“Outset′′), a medical technology company pioneering a first-of-its-kind Technology to reduce the cost and complexity of dialysis, today announced two new research posters that demonstrate significant quality of life and mental health benefits for patients and their caregivers using its Tablo® Hemodialysis System for home hemodialysis (HHD). “As physicians, we understand that a critical component of effective treatment includes not just providing physical relief, but also addressing the very real and challenging emotional aspects of managing end-stage kidney disease,” said Michael Aragon, MD, Chief Medical Officer of Outset Medical.“Our poster presentations at Kidney Week 2024 provide real-world evidence that Tablo is effective at helping both those in need of dialysis and their caregivers take back their life and build confidence in their treatment.
Positive mental health and quality of life are essential factors in making this a reality.” The following posters will be presented at Kidney Week 2024: Improvement in Depression and Quality of Life in HHD Patients : Patients with end-stage renal disease (ESRD) commonly report depressive symptoms (e.g.
, feelin.
